LDK378: A promising anaplastic lymphoma kinase (ALK) inhibitor

Journal of Medicinal Chemistry

Volumn 56, Issue 14, 2013, Pages 5673-5674

  Chen, Jianyong ^a   Jiang, Cheng ^a   Wang, Shaomeng ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; ASP 3026; CH 5424802; CRIZOTINIB; LDK 378; PROTEIN TYROSINE KINASE INHIBITOR; TAE 684; UNCLASSIFIED DRUG; X 396;

ANTIPROLIFERATIVE ACTIVITY; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; DRUG APPROVAL; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; LUNG NON SMALL CELL CANCER; NONHUMAN; NOTE; TREATMENT RESPONSE;

ANIMALS; HUMANS; MALE; NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; SULFONES;

EID: 84880889769     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401005u     Document Type: Note

References (7)

1. Webb, T. R.; Slavish, J.; George, R. E.; Look, A. T.; Xue, L.; Jiang, Q.; Cui, X.; Rentrop, W. B.; Morris, S. W. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy Expert Rev. Anticancer Ther. 2009, 9, 331-356
2. Griffin, C. A.; Hawkins, A. L.; Dvorak, C.; Henkle, C.; Ellingham, T.; Perlman, E. J. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors Cancer Res. 1999, 59, 2776-2780
3. Gascoyne, R. D.; Lamant, L.; Martin-Subero, J. I.; Lestou, V. S.; Harris, N. L.; Muller-Hermelink, H. K.; Seymour, J. F.; Campbell, L. J.; Horsman, D. E.; Auvigne, I.; Espinos, E.; Siebert, R.; Delsol, G. ALK-positive diffuse large B-cell lymphoma is associated with clathrin-ALK rearrangements: report of 6 cases Blood 2003, 102, 2568-2573
4. Jazii, F. R.; Najafi, Z.; Malekzadeh, R.; Conrads, T. P.; Ziaee, A. A.; Abnet, C.; Yazdznbod, M.; Karkhane, A. A.; Salekdeh, G. H. Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer World J. Gastroenterol. 2006, 12, 7104-7112
5. Soda, M.; Choi, Y. L.; Enomoto, M.; Takada, S.; Yamashita, Y.; Ishikawa, S.; Fujiwara, S.; Watanabe, H.; Kurashina, K.; Hatanaka, H.; Bando, M.; Ohno, S.; Ishikawa, Y.; Aburatani, H.; Niki, T.; Sohara, Y.; Sugiyama, Y.; Mano, H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 2007, 448, 561-566
6. Marsilje, T. H.; Pei, W.; Chen, B.; Lu, W.; Uno, T.; Jin, Y.; Jiang, T.; Kim, S.; Li, N.; Warmuth, M.; Sarkisova, Y.; Sun, F.; Steffy, A.; Pferdekamper, A. C.; Li, A. G.; Joseph, S. B.; Kim, Y.; Liu, B.; Tuntland, T.; Cui, X.; Gray, N. S.; Steensma, R.; Wan, Y.; Jiang, J.; Chopiuck, G.; Li, J.; Gordon, W. P.; Richmond, W.; Johnson, K.; Chang, J.; Groessl, T.; He, Y.-Q.; Phimister, A.; Aycinena, A.; Lee, C. C.; Bursulaya, B.; Karanewsky, D. S.; Seidel, H. M.; Harris, J. L.; Michellys, P.-Y. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro- N 2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)- N 4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J. Med. Chem. 2013, DOI: 10.1021/jm400402q.
7. Galkin, A. V.; Melnick, J. S.; Kim, S.; Hood, T. L.; Li, N.; Li, L.; Xia, G.; Steensma, R.; Chopiuk, G.; Jiang, J.; Wan, Y.; Ding, P.; Liu, Y.; Sun, F.; Schultz, P. G.; Gray, N. S.; Warmuth, M. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 270-275